Literature DB >> 15717075

[Monitoring and evaluation of side effects of chemotherapy in patients with colon cancer].

Elizabeth Pinto Magalhães de Almeida1, Maria Gaby Rivero de Gutiérrez, Nilce Piva Adami.   

Abstract

This study aimed to monitor and evaluate the occurrence and intensity level of nausea, vomiting and diarrhea in patients with colon cancer, submitted to outpatient chemotherapy, who received nursing information for handling these symptoms. Study participants were 17 patients, who were treated with 5-Fluorouracil and low doses of folinic acid, at the Adult Outpatient Chemotherapy Clinic of the Hospital São Paulo/Federal University of São Paulo, Brazil. Instruments were elaborated for registering these symptoms' occurrence and intensity level and a patient guide for handling them. The information and patient monitoring were carried out by the nurse during the consultations. The results showed that most of the patients (82.4%) displayed at least one of the signs and symptoms under study between the first and the 21st day of the treatment cycle. Nausea was the most frequent symptom (76.5%), with a peak on the 4th and 5th day of the cycle, followed by diarrhea (70.5%), with a peak on the 7th day, and vomiting (53.0%), with a peak on the 5th day. Regarding the intensity of these symptoms, most patients were classified as level 1, which was established as acceptable for this study. These results indicate that the nursing instructions and the continuous monitoring contributed to the effectiveness of the patient's symptom management.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15717075     DOI: 10.1590/s0104-11692004000500009

Source DB:  PubMed          Journal:  Rev Lat Am Enfermagem        ISSN: 0104-1169


  5 in total

Review 1.  Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.

Authors:  Tobias Engel Ayer Botrel; Otávio Augusto C Clark; Luciana Clark; Luciano Paladini; Enéas Faleiros; Bruna Pegoretti
Journal:  Support Care Cancer       Date:  2010-05-22       Impact factor: 3.603

2.  Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.

Authors:  Young Mi Seol; Hyo Jeong Kim; Young Jin Choi; Eun Mi Lee; Yang Soo Kim; Sung Yong Oh; Su Jin Koh; Jin Ho Baek; Won Sik Lee; Young Don Joo; Hyun Gi Lee; Eun Young Yun; Joo Seop Chung
Journal:  Support Care Cancer       Date:  2015-08-12       Impact factor: 3.603

3.  Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer.

Authors:  Jin Soo Kim; Ji Yeon Kim; Sang-Jeon Lee; Dong Kook Park; Hwan Namgung; Chang Nam Kim; Won Jun Choi; Moo Jun Baek
Journal:  Ann Surg Treat Res       Date:  2014-06-24       Impact factor: 1.859

Review 4.  The various aspects of genetic and epigenetic toxicology: testing methods and clinical applications.

Authors:  Ning Ren; Manar Atyah; Wan-Yong Chen; Chen-Hao Zhou
Journal:  J Transl Med       Date:  2017-05-22       Impact factor: 5.531

5.  Serum Oxidative Stress Markers and Genotoxic Profile Induced by Chemotherapy in Patients with Breast Cancer: A Pilot Study.

Authors:  Antonio Luiz Gomes Júnior; Marcia Fernanda Correia Jardim Paz; Laís Iasmin Soares da Silva; Simone da Costa e Silva Carvalho; André Luiz Pinho Sobral; Kátia da Conceição Machado; Paulo Michel Pinheiro Ferreira; Prabodh Satyal; Rivelilson Mendes de Freitas; Ana Amélia de Carvalho Melo Cavalcante
Journal:  Oxid Med Cell Longev       Date:  2015-10-20       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.